CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Review CIRB
Study Status
Study Number Sort descending Lead Group Study Title CIRB Study Status
9149 ETCTN Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors Adult CIRB - Late Phase Emphasis Available to Open
9466 ETCTN Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only) Adult CIRB - Early Phase Emphasis Available to Open
9571 ETCTN A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer Adult CIRB - Early Phase Emphasis Completed
9608 ETCTN A Phase I Trial of ABT-263 (Navitoclax); a Bcl-2 inhibitor; and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors Adult CIRB - Early Phase Emphasis Available to Open
9653 ETCTN Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Unrothelial Carcinoma of the Bladder Adult CIRB - Early Phase Emphasis Completed
9671 ETCTN Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are Exceptional responders Adult CIRB - Early Phase Emphasis Completed
9672 ETCTN A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus Adult CIRB - Early Phase Emphasis Completed
9673 ETCTN PART A: A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal PART B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal Adult CIRB - Early Phase Emphasis Available to Open
9676 ETCTN A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
9681 ETCTN A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors. Adult CIRB - Early Phase Emphasis Available to Open